|
|
Volumn 20, Issue 5, 2005, Pages 417-428
|
|
Evaluation of O3α-,O21-Di- (N1-methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl) 17α-hydroxy-5β-pregnan-20-one as a novel potential antiangiogenic codrug
a
a
a
a
|
|
Author keywords
5 Fluorouracil; 5FU; Angiogenesis; Codrug; Sustained release; THS
|
|
Indexed keywords
17ALPHA,20:20,21 BIS(METHYLENEDIOXY) 3ALPHA HYDROXY 5BETA PREGNANE;
17ALPHA,20:20,21 BIS(METHYLENEDIOXY) 5BETA PREGNAN 3 ONE;
17ALPHA,20:20,21 BIS(METHYLENEDIOXY)PREGN 4 ENE 3 ONE;
3ALPHA,17BETA,21 TRIHYDROXY 5BETA PREGNAN 20 ONE;
ANGIOGENESIS INHIBITOR;
FLUOROURACIL;
HYDROXYSTEROID;
N1,N3 DI(HYDROXYMETHYL) 5 FLUOROURACIL;
O3ALPHA,O21 DI(CHLOROFORMYL) 17ALPHA HYDROXY 5BETA PREGNAN 20 ONE;
O3ALPHA,O21 DI(N1 METHYLOXYCARBONYL 2,4 DIOXO 5 FLUOROPYRIMIDINYL) 17ALPHA HYDROXY 5BETA PREGNAN 20 ONE;
UNCLASSIFIED DRUG;
DRUG DERIVATIVE;
ELTANOLONE;
O(3ALPHA) ,O(21) DI (N(1) METHYLOXYCARBONYL 2, 4 DIOXO 5 FLUOROPYRIMIDINYL) 17ALPHA HYDROXY 5BETA PREGNAN 20 ONE;
O(3ALPHA)-,O(21)-DI-(N(1)-METHYLOXYCARBONYL-2, 4-DIOXO-5-FLUOROPYRIMIDINYL)-17ALPHA-HYDROXY-5BETA-PREGNAN-20-ONE;
ANIMAL TISSUE;
ANTIANGIOGENIC ACTIVITY;
ARTICLE;
CHORIOALLANTOIS;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
DRUG EFFICACY;
DRUG MIXTURE;
DRUG POTENTIATION;
DRUG RELEASE;
DRUG SOLUBILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
EMBRYO;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
NONHUMAN;
PRIORITY JOURNAL;
ANIMAL;
BIOAVAILABILITY;
CATTLE;
CHEMICAL STRUCTURE;
CHEMISTRY;
CHICKEN;
CYCLIZATION;
DRUG COMBINATION;
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;
SOLUBILITY;
SYNTHESIS;
ANIMALIA;
ANGIOGENESIS INHIBITORS;
ANIMALS;
BIOLOGICAL AVAILABILITY;
CATTLE;
CHICKENS;
CYCLIZATION;
DRUG THERAPY, COMBINATION;
FLUOROURACIL;
HUMANS;
MAGNETIC RESONANCE SPECTROSCOPY;
MOLECULAR STRUCTURE;
PREGNANOLONE;
SOLUBILITY;
|
|
EID: 28244497016
PISSN: 14756366
EISSN: 14756374
Source Type: Journal
DOI: 10.1080/14756360500220319 Document Type: Article |
|
Times cited : (9)
|
|
References (28)
|
